|
Post by mnkdfann on Dec 24, 2016 9:19:31 GMT -5
[ "Sanofi clearly stated through their agents to the press in January, when they cancelled the partnership with MNKD, that Afrezza could not be commercialized" I've read numerous articles about the partnership cancellation, but none saying what you just said. Would you please provide a link to an article where Sanofi said this? Thanks in advance. Brotherm, Not to speak for surplus, but until he/she responds... I think that was paraphrasing what Sanofi said, not a direct quote, because I read them as well. If my memory serves me correctly, Sanofi said that AFREZZA could not be commercially successful, or was not commercially viable. Words to that effect nonetheless! Hopefully someone finds the exact verbiage to put it to rest. Yes, words to that effect. See Sanofi memo at the bottom of this page. www.statnews.com/pharmalot/2016/01/05/insulin-sanofi-diabetes/
|
|
|
Post by agedhippie on Dec 24, 2016 10:17:44 GMT -5
Mike: You've been here since Dec 18th and already created two threads about Sanofi and MNKD. Sanofi clearly stated through their agents to the press in January, when they cancelled the partnership with MNKD, that Afrezza couldnt be commercialized. End of story. The legal repercussions of Sanofi coming back would be catastrophic. You're like the guy whose old girlfriend broke up with him in high school and you never were able to accept it or get over it. It's over. Time to move on. If you want to live in fantasy island, that's fine ...but do everyone else here a favour and don't post about it. The very best to you for the holidays and new year. [ "Sanofi clearly stated through their agents to the press in January, when they cancelled the partnership with MNKD, that Afrezza could not be commercialized" I've read numerous articles about the partnership cancellation, but none saying what you just said. Would you please provide a link to an article where Sanofi said this? Thanks in advance. It's implicit in Article 12 of the partnership agreement. This is confirmed by the 8K that Mannkind filed on the termination. The 8K says, " Sanofi’s notice indicated that the termination was pursuant to Sanofi’s right to terminate the License Agreement upon Sanofi’s good faith determination that the commercialization of AFREZZA is no longer economically viable in the United States, in which case the effective date of termination will be April 3, 2016." So either Mannkind lied to the SEC, or Sanofi terminated because Afrezza was not commercially viable in their view. As to the view that Sanofi could pick up Afrezza again - it could but that is inviting a law suit. Some ambulance chaser would be all over that deposing people to prove that they knew it was viable at the point of the statement and hence defrauded shareholders.
|
|
|
Post by 2011mnkdguy on Dec 24, 2016 11:18:07 GMT -5
[ "Sanofi clearly stated through their agents to the press in January, when they cancelled the partnership with MNKD, that Afrezza could not be commercialized" I've read numerous articles about the partnership cancellation, but none saying what you just said. Would you please provide a link to an article where Sanofi said this? Thanks in advance. It's implicit in Article 12 of the partnership agreement. This is confirmed by the 8K that Mannkind filed on the termination. The 8K says, " Sanofi’s notice indicated that the termination was pursuant to Sanofi’s right to terminate the License Agreement upon Sanofi’s good faith determination that the commercialization of AFREZZA is no longer economically viable in the United States, in which case the effective date of termination will be April 3, 2016." So either Mannkind lied to the SEC, or Sanofi terminated because Afrezza was not commercially viable in their view. As to the view that Sanofi could pick up Afrezza again - it could but that is inviting a law suit. Some ambulance chaser would be all over that deposing people to prove that they knew it was viable at the point of the statement and hence defrauded shareholders. Or it shows Sanofi lied(acted) in bad faith.
|
|
|
Post by agedhippie on Dec 24, 2016 12:25:55 GMT -5
It's implicit in Article 12 of the partnership agreement. This is confirmed by the 8K that Mannkind filed on the termination. The 8K says, " Sanofi’s notice indicated that the termination was pursuant to Sanofi’s right to terminate the License Agreement upon Sanofi’s good faith determination that the commercialization of AFREZZA is no longer economically viable in the United States, in which case the effective date of termination will be April 3, 2016." So either Mannkind lied to the SEC, or Sanofi terminated because Afrezza was not commercially viable in their view. As to the view that Sanofi could pick up Afrezza again - it could but that is inviting a law suit. Some ambulance chaser would be all over that deposing people to prove that they knew it was viable at the point of the statement and hence defrauded shareholders. Or it shows Sanofi lied(acted) in bad faith. If Sanofi lied then so did Mannkind when they accepted the termination rather than dispute it. The truth of the matter is that Sanofi had a case and it could not be disputed. Would a different strategy have had a different outcome? Maybe but this was the strategy chosen and agreed by the parties.
|
|
|
Post by careful2invest on Dec 24, 2016 13:42:59 GMT -5
Or it shows Sanofi lied(acted) in bad faith. If Sanofi lied then so did Mannkind when they accepted the termination rather than dispute it. The truth of the matter is that Sanofi had a case and it could not be disputed. Would a different strategy have had a different outcome? Maybe but this was the strategy chosen and agreed by the parties. This topic may deserve it's own thread, but isn't it strange that Sanofi still has a deal with Verily pertaining to inhaled insulin, yet Mannkind has the only inhaleable insulin? Has there been any additional news in relation to this point? Or did I miss a press release or SEC report.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 24, 2016 13:57:49 GMT -5
If Sanofi lied then so did Mannkind when they accepted the termination rather than dispute it. The truth of the matter is that Sanofi had a case and it could not be disputed. Would a different strategy have had a different outcome? Maybe but this was the strategy chosen and agreed by the parties. This topic may deserve it's own thread, but isn't it strange that Sanofi still has a deal with Verily pertaining to inhaled insulin, yet Mannkind has the only inhaleable insulin? Has there been any additional news in relation to this point? Or did I miss a press release or SEC report. the article of sanofi/verily deal cited inhaled insulin cos Sanofi was distrubuting the insulin at the time and the author mentioned it. Doesnt mean the deal was about Afrezza. Verily is more interested in data and IBM as well. I am not sure why some people dont get it even when repeatedly many posters here clarified.
|
|
|
Post by rockstarrick on Dec 24, 2016 15:47:55 GMT -5
This topic may deserve it's own thread, but isn't it strange that Sanofi still has a deal with Verily pertaining to inhaled insulin, yet Mannkind has the only inhaleable insulin? Has there been any additional news in relation to this point? Or did I miss a press release or SEC report. the article of sanofi/verily deal cited inhaled insulin cos Sanofi was distrubuting the insulin at the time and the author mentioned it. Doesnt mean the deal was about Afrezza. Verily is more interested in data and IBM as well. I am not sure why some people dont get it even when repeatedly many posters here clarified. I'm not arguing your point, but you must agree, statements like this one from the very first article announcing the Google and Sanofi alliance along with other statements made in this and other articles sure make it sound like INHALED Insulin was a strong basis for the alliance. Google Life Sciences earlier this week announced a partnership with Sanofi, maker of an insulin inhaler and a slew of other products for people with diabetes. Google is also working with Johnson & Johnson on surgical robots, Biogen on potential treatments for multiple sclerosis and Novartis and Dexcom on diabetes-related projects. www.npr.org/sections/health-shots/2015/09/06/437570402/why-google-is-going-all-in-on-diabetesIt wouldnt surprise me in the least to see afrezza wind up right in the middle of real time Diabetes monitoring and glucose control. Merry Christmas Iam
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 24, 2016 16:01:30 GMT -5
the article of sanofi/verily deal cited inhaled insulin cos Sanofi was distrubuting the insulin at the time and the author mentioned it. Doesnt mean the deal was about Afrezza. Verily is more interested in data and IBM as well. I am not sure why some people dont get it even when repeatedly many posters here clarified. I'm not arguing your point, but you must agree, statements like this one from the very first article announcing the Google and Sanofi alliance along with other statements made in this and other articles sure make it sound like INHALED Insulin was a strong basis for the alliance. Google Life Sciences earlier this week announced a partnership with Sanofi, maker of an insulin inhaler and a slew of other products for people with diabetes. Google is also working with Johnson & Johnson on surgical robots, Biogen on potential treatments for multiple sclerosis and Novartis and Dexcom on diabetes-related projects. www.npr.org/sections/health-shots/2015/09/06/437570402/why-google-is-going-all-in-on-diabetesIt wouldnt surprise me in the least to see afrezza wind up right in the middle of real time Diabetes monitoring and glucose control. Merry Christmas Iam Sanofi, maker of an insulin inhaler and a slew of other products
|
|
|
Post by mikesmilitaria on Dec 24, 2016 16:26:07 GMT -5
I think the CFO at any corporation, no matter what the revenue, would disagree that $75mm is nothing. You need some assistance in economics pal.
|
|
|
Post by rockstarrick on Dec 24, 2016 16:28:46 GMT -5
I'm not arguing your point, but you must agree, statements like this one from the very first article announcing the Google and Sanofi alliance along with other statements made in this and other articles sure make it sound like INHALED Insulin was a strong basis for the alliance. Google Life Sciences earlier this week announced a partnership with Sanofi, maker of an insulin inhaler and a slew of other products for people with diabetes. Google is also working with Johnson & Johnson on surgical robots, Biogen on potential treatments for multiple sclerosis and Novartis and Dexcom on diabetes-related projects. www.npr.org/sections/health-shots/2015/09/06/437570402/why-google-is-going-all-in-on-diabetesIt wouldnt surprise me in the least to see afrezza wind up right in the middle of real time Diabetes monitoring and glucose control. Merry Christmas Iam Sanofi, maker of an insulin inhaler and a slew of other productsAs I said, I'm not arguing your point, all I'm saying is I can see where some would see differently because the only Insulin inhaler Sanofi Owned any part of was the Dreamboat. I do stand by my statement that afrezza will be part of the realtime glucose monitoring and control in some way. It may take time, and it's just my opinion, but I think I'll be right. As for Sanofi, I wouldn't piss in their ear if their brains were on fire 🔥 Im glad they're gone. Have a great Holiday Season
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 24, 2016 17:33:35 GMT -5
Sanofi, maker of an insulin inhaler and a slew of other productsAs I said, I'm not arguing your point, all I'm saying is I can see where some would see differently because the only Insulin inhaler Sanofi Owned any part of was the Dreamboat. I do stand by my statement that afrezza will be part of the realtime glucose monitoring and control in some way. It may take time, and it's just my opinion, but I think I'll be right. As for Sanofi, I wouldn't piss in their ear if their brains were on fire 🔥 Im glad they're gone. Have a great Holiday Season any diabetes product will be - its all about monitoring and collecting the data I know some will spin..i said so lol
|
|
|
Post by sportsrancho on Dec 24, 2016 17:42:39 GMT -5
SNY will be back...but they'll want the whole enchilada:-))) Many days late, and many dollars short. ( Just had to say it:-)
|
|
|
Post by agedhippie on Dec 24, 2016 18:10:51 GMT -5
the article of sanofi/verily deal cited inhaled insulin cos Sanofi was distrubuting the insulin at the time and the author mentioned it. Doesnt mean the deal was about Afrezza. Verily is more interested in data and IBM as well. I am not sure why some people dont get it even when repeatedly many posters here clarified. I'm not arguing your point, but you must agree, statements like this one from the very first article announcing the Google and Sanofi alliance along with other statements made in this and other articles sure make it sound like INHALED Insulin was a strong basis for the alliance. Google Life Sciences earlier this week announced a partnership with Sanofi, maker of an insulin inhaler and a slew of other products for people with diabetes. Google is also working with Johnson & Johnson on surgical robots, Biogen on potential treatments for multiple sclerosis and Novartis and Dexcom on diabetes-related projects. www.npr.org/sections/health-shots/2015/09/06/437570402/why-google-is-going-all-in-on-diabetesIt wouldnt surprise me in the least to see afrezza wind up right in the middle of real time Diabetes monitoring and glucose control. Merry Christmas Iam The problem is that you are taking a secondhand version of the story. If you want to see what the 2015 agreement was really about rather than what NPR thought it was about look at the official press release - that's the definitive source. The press release bullets the mission at the top: Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes - Will work together on new digital technology and tools for diabetes -
- Aim to use data and miniaturized technology to provide patients with more tools to self-manage their disease, healthcare professionals with the ability to better support and treat patients -
- Strive to shift from episodic, event-driven diabetes care to continuous, value-based care - This is about data and not drugs. That is the entire focus as reading the the press release makes clear. Afrezza gets a single peripheral mention at best in the About Sanofi Diabetes section where amongst other things it says, "Sanofi markets injectable, inhaled and oral medications for people with type 1 or type 2 diabetes." That's it.
|
|
|
Post by agedhippie on Dec 24, 2016 18:31:14 GMT -5
If Sanofi lied then so did Mannkind when they accepted the termination rather than dispute it. The truth of the matter is that Sanofi had a case and it could not be disputed. Would a different strategy have had a different outcome? Maybe but this was the strategy chosen and agreed by the parties. This topic may deserve it's own thread, but isn't it strange that Sanofi still has a deal with Verily pertaining to inhaled insulin, yet Mannkind has the only inhaleable insulin? Has there been any additional news in relation to this point? Or did I miss a press release or SEC report. You missed a huge one, the announcement of Onduo in 2016 Even before there was never an agreement pertaining to inhaled insulin, the agreement covered the whole Sanofi diabetes portfolio including their oral drugs, non-insulin injectables, and all their insulins. Afrezza was just one drug in the portfolio, it had no more special significance in the relationship than, say, Apidra. The agreements are clear on this - see the 8K.
|
|
|
Post by rockstarrick on Dec 24, 2016 18:38:12 GMT -5
As I said, I'm not arguing your point, all I'm saying is I can see where some would see differently because the only Insulin inhaler Sanofi Owned any part of was the Dreamboat. I do stand by my statement that afrezza will be part of the realtime glucose monitoring and control in some way. It may take time, and it's just my opinion, but I think I'll be right. As for Sanofi, I wouldn't piss in their ear if their brains were on fire 🔥 Im glad they're gone. Have a great Holiday Season any diabetes product will be - its all about monitoring and collecting the data I know some will spin..i said so lol Agree, it is the combination of both basal and prandial Insulin that is producing the time in zone PWD are seeing, PWD using afrezza seem to be doing better IMO.
|
|